Please sign in to follow a disease.
Histiocytic sarcoma
MONDO:0019479An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.
Also known as: histiocytic sarcoma, sarcoma, histiocytic, malignant
1853 clinical trials for this condition and its sub-types, 9 tagged with Histiocytic sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Last-Resort drug access opens for rare tumor patients
Disease control Expanded accessThis program provides mirdametinib to individual patients with serious, life-threatening conditions like neurofibromatosis type 1 tumors or other MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the comp…
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill Q702 aims to outsmart blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Targeted drug cobimetinib tested for rare immune cell cancers
Disease control Recruiting nowThis phase 2 study tests the drug cobimetinib in children and adults with Langerhans cell histiocytosis and related disorders that have come back or not responded to standard treatment. Cobimetinib blocks a growth signal that goes haywire in these diseases. The study will enroll …
Phase 2 • Sponsor: Carl Allen • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Massive study tracks hidden toll of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 6,000 people with histiocytic disorders (like Langerhans cell histiocytosis) to understand long-term health problems, pain, mental health, and causes of death. Researchers compare participants to healthy controls to identify factors that lead to new health issu…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC